BioCentury
ARTICLE | Clinical News

ProQR planning pivotal trial of vision loss candidate

September 5, 2018 8:49 PM UTC

ProQR Therapeutics N.V. (NASDAQ:PRQR) jumped $9.60 (121%) to $17.55 on Wednesday after the company said it plans to start the pivotal Phase II/III ILLUMINATE trial of QR-110 next half to treat Leber congenital amaurosis type 10 (LCA10) caused by the p.Cys998X mutation in the centrosomal protein 290kDa (CEP290) gene. The decision was based on newly released interim data from the Phase I/II PQ-110-001 trial showing that the candidate led to rapid and sustained visual improvements at three months.

After market close on Wednesday, ProQR proposed to raise $75 million in a follow-on underwritten by Citigroup, Evercore ISI and RBC Capital Markets...

BCIQ Company Profiles

ProQR Therapeutics N.V.